{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:22:46Z","timestamp":1794072166815,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.annder.2026.103487","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:40:25Z","timestamp":1776732025000},"page":"103487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of immune checkpoint inhibitors in patients with xeroderma pigmentosum and advanced cutaneous squamous-cell carcinoma and literature review"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1588-4309","authenticated-orcid":false,"given":"M.","family":"Dumas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"R\u00e9guerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Scalbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bertolotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Miquel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2026.103487_b0005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/jmg.2010.083022","article-title":"Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair","volume":"48","author":"Bradford","year":"2011","journal-title":"J Med Genet"},{"key":"10.1016\/j.annder.2026.103487_b0010","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.dnarep.2011.03.005","article-title":"A new XPC gene splicing mutation has lead to the highest worldwide prevalence of xeroderma pigmentosum in black Mahori patients","volume":"10","author":"Cartault","year":"2011","journal-title":"DNA Rep"},{"key":"10.1016\/j.annder.2026.103487_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1282823","article-title":"Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers","volume":"13","author":"Fernandez","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.annder.2026.103487_b0020","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26837","article-title":"Dramatic response to nivolumab in xeroderma pigmentosum skin tumor","volume":"65","author":"Chambon","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.annder.2026.103487_b0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2026.103487_b0030","article-title":"Response to pembrolizumab in a patient with xeroderma pigmentosum and advanced squamous cell carcinoma","volume":"3","author":"Steineck","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annder.2026.103487_b0035","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.annder.2026.103487_b0040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2017.02.026","article-title":"Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab","volume":"77","author":"Hauschild","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2026.103487_b0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2017.06.022","article-title":"Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature","volume":"83","author":"Deinlein","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2026.103487_b0050","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/bjd.16270","article-title":"Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum","volume":"178","author":"Salomon","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2026.103487_b0055","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/bjd.18144","article-title":"Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum","volume":"181","author":"Ameri","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2026.103487_b0060","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.18632\/oncotarget.27966","article-title":"Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review","volume":"12","author":"Rubatto","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.annder.2026.103487_b0065","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1080\/0284186X.2022.2109425","article-title":"Efficacy of pembrolizumab in a patient with xeroderma pigmentosum variant and advanced cutaneous squamous-cell carcinoma","volume":"61","author":"Hennemann","year":"2022","journal-title":"Acta Oncol Stockh Swed"},{"key":"10.1016\/j.annder.2026.103487_b0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2022.06.050","article-title":"Three-year disease-free remission in a xeroderma pigmentosum patient after adjuvant anti-PD-1 therapy","volume":"173","author":"Scheer","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2026.103487_b0075","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s13256-022-03524-2","article-title":"Recurrent squamous cell carcinoma and a novel mutation in a patient with xeroderma pigmentosum: a case report","volume":"16","author":"\u015eahin","year":"2022","journal-title":"J Med Case Reports"},{"key":"10.1016\/j.annder.2026.103487_b0080","article-title":"Can Cemiplimab become a life-changer in xeroderma pigmentosum?","volume":"13","author":"Boziou","year":"2023","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.annder.2026.103487_b0085","first-page":"312","article-title":"Successful use of anti-PD-1 antibody to treat multiple metastatic carcinomas in a patient with xeroderma pigmentosum: case report and literature review","volume":"5","author":"Itoyama","year":"2023","journal-title":"Clin Image Case Rep J"},{"key":"10.1016\/j.annder.2026.103487_b0090","article-title":"Case report: neoadjuvant-intent pembrolizumab resulted in complete response in a xeroderma pigmentosum patient with locally advanced resectable cutaneous squamous cell carcinoma of the nose","volume":"11","author":"Zalaquett","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.annder.2026.103487_b0095","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000775","article-title":"Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing","volume":"8","author":"Rischin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annder.2026.103487_b0100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annder.2026.103487_b0105","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.annder.2018.11.013","article-title":"Skin cancers in patients of skin phototype V or VI with xeroderma pigmentosum type C (XP-C): a retrospective study","volume":"146","author":"Vent\u00e9jou","year":"2019","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2026.103487_b0110","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","article-title":"Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annder.2026.103487_b0115","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1001\/jamaoto.2024.0259","article-title":"Neoadjuvant-intent immunotherapy in advanced, resectable cutaneous squamous cell carcinoma","volume":"150","author":"Kim","year":"2024","journal-title":"JAMA Otolaryngol Neck Surg"},{"key":"10.1016\/j.annder.2026.103487_b0120","article-title":"Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cutaneous squamous cell carcinoma (cSCC)","author":"Sridharan","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2026.103487_b0125","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1470-2045(23)00459-X","article-title":"Neoadjuvant cemiplimab and surgery for stage II\u2013IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study","volume":"24","author":"Gross","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annder.2026.103487_b0130","article-title":"Benefit of immunotherapy for advanced melanoma in two patients with xeroderma pigmentosum","volume":"2","author":"Segovia","year":"2024","journal-title":"EJC Skin Cancer"},{"key":"10.1016\/j.annder.2026.103487_b0135","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13023-022-02203-1","article-title":"Increased risk of internal tumors in DNA repair-deficient xeroderma pigmentosum patients: analysis of four international cohorts","volume":"17","author":"Nikolaev","year":"2022","journal-title":"Orphanet J Rare Dis"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963826000219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963826000219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:45:32Z","timestamp":1781124332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963826000219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0151963826000219"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2026.103487","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of immune checkpoint inhibitors in patients with xeroderma pigmentosum and advanced cutaneous squamous-cell carcinoma and literature review","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2026.103487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103487"}}